New Therapeutic Strategies of Radioresistant Tumours by Radiosensitization

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".

Deadline for manuscript submissions: 15 January 2025 | Viewed by 1278

Special Issue Editors

Department of Life and Environmental Physics, Horia Hulubei National Institute of Physics and Nuclear Engineering, 077125 Magurele, Romania
Interests: radioresistant cancer cell biology; tumor cell radiosensitization; DNA damage signaling; mitochondria–nucleus communication; radiation-induced bystander effects; radiation response biomarkers; tumor microenvironment
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
UMR6252 CIMAP—Centre de Recherche sur les Ions, les MAtériaux et la Photonique Team ARIA, Applications in Radiobiology with Accelerated Ions Campus Jules, Horowitz, Bd Henri Becquerel, BP 55027, F-14076 Caen, Cedex 05, France
Interests: cancer cell biology; radiotherapy; particle therapy; DNA damage response; signaling transduction; radiation-induced bystander effects; tumor cell radiosensitization; integrated omics; proteomics; radiation response biomarkers; radioresistance; combined treatments; tumor microenvironment; inflammatory
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

In recent years, cancer therapy has advanced substantially, thus significantly enhancing the quality of life of cancer patients. However, successful tumor therapy remains a major challenge, particularly in tumors that are resistant to chemo or radiation therapy. The main factor in determining the therapeutic effect is the tumor’s response to radiation, which is correlated with intrinsic or acquired radioresistance after treatment. Consequently, future research must continue to advance our comprehension of the fundamental mechanisms of chemo and radiation resistance when it is related to target mutations, the tumor microenvironment and signaling pathways in cancers. This is in order to identify novel biomarkers and to develop new radiosensitizers and combined strategies that are able to overcome the resistance of tumors to therapy. This Special Issue aims to collect current research in the realm of tumor radiosensitizers, the fundamental mechanisms of radioresistance and the identification of novel biomarkers. Potential topics include, but are not limited to, the following:

  • Tumor drug radiosensitizers
  • Tumor nanoparticle radiosensitizers
  • Fundamental mechanisms of resistance
  • Novel biomarkers
  • Innovative combined treatments
  • Chemo- and radiation-resistant tumors

Dr. Diana Savu
Dr. François Chevalier
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • chemo-radiation-resistant tumors
  • radiosensitizers
  • biomarkers
  • mechanisms of radioresistance
  • tumor drug radiosensitizers

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

14 pages, 2651 KiB  
Article
Overexpression of Growth Differentiation Factor 15 in Glioblastoma Stem Cells Promotes Their Radioresistance
by Alexandre Bentaberry-Rosa, Yvan Nicaise, Caroline Delmas, Valérie Gouazé-Andersson, Elizabeth Cohen-Jonathan-Moyal and Catherine Seva
Cancers 2024, 16(1), 27; https://doi.org/10.3390/cancers16010027 - 20 Dec 2023
Viewed by 943
Abstract
GSCs play an important role in GBM recurrence. Understanding the resistance mechanisms in these cells is therefore crucial for radiation therapy optimization. In this study, using patient-derived GSCs, we demonstrate that GDF15, a cytokine belonging to the TGF-β superfamily, is regulated by irradiation [...] Read more.
GSCs play an important role in GBM recurrence. Understanding the resistance mechanisms in these cells is therefore crucial for radiation therapy optimization. In this study, using patient-derived GSCs, we demonstrate that GDF15, a cytokine belonging to the TGF-β superfamily, is regulated by irradiation (IR) and the transcription factor WWTR1/TAZ. Blocking WWTR1/TAZ using specific siRNAs significantly reduces GDF15 basal expression and reverses the upregulation of this cytokine induced by IR. Furthermore, we demonstrate that GDF15 plays an important role in GSC radioresistance. Targeting GDF15 expression by siRNA in GSCs expressing high levels of GDF15 sensitizes the cells to IR. In addition, we also found that GDF15 expression is critical for GSC spheroid formation, as GDF15 knockdown significantly reduces the number of GSC neurospheres. This study suggests that GDF15 targeting in combination with radiotherapy may be a feasible approach in patients with GBM. Full article
Show Figures

Figure 1

Back to TopTop